SBI links with Chinese biotech for nucleotide drugs
This article was originally published in Scrip
Executive Summary
The Japanese bioventure SBI Biotech has entered into a collaboration with China's Changchun Huapu Biotechnology to develop novel nucleotide therapeutics. The deal gives SBI certain rights to co-develop three Changchun projects in markets including the US, China and/or Japan. Changchun has developed a novel class of therapies which target dendritic and malignant B-cells and modulate immune response. SBI intends to investigate the possible combination of these with antibodies and other immunotherapies, president and CEO Dr Ken-ichi Araisaid.